Literature DB >> 10556189

Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment.

P B van Hennik1, A E de Koning, R E Ploemacher.   

Abstract

Nonobese diabetic/severe combined immune deficiency (NOD/SCID) mouse repopulating cells (SRC) have been proposed to represent a more primitive human stem cell subset than the cobblestone area-forming cell (CAFC) week (wk) 6 or the long-term culture-initiating cell (LTC-IC) wk 5 on the basis of their difference in frequency, phenotype, transfectibility, and multilineage outgrowth potential in immunodeficient recipients. We have assessed the percentage of various progenitor cell populations (colony-forming cell [CFC] and CAFC subsets) contained in unsorted NOD/SCID BM nucleated cells (nc), human umbilical cord blood (UCB) nc, bone marrow (BM) nc, peripheral blood stem cells (PBSC), and CD34(+) selected UCB nc, seeding in the BM and spleen of NOD/SCID mice within 24 hours after transplantation. The seeding efficiency of NOD/SCID BM CAFC wk 5 was median (range) in the spleen 2.9% (0.7% to 4.0%) and in the total BM 8.7% (2.0% to 9.2%). For human unsorted UCB nc, BM nc, PBSC, and CD34(+) UCB cells, the seeding efficiency for CAFC wk 6 in the BM of NOD/SCID mice was 4.4% (3.5% to 6.3%), 0.8% (0.3% to 1.7%), 5.3% (1. 4% to 13.6%), and 4.4% (3.5% to 6.3%), respectively. Using flow cytometry, the percentage CD34(+) UCB cells retrieved from the BM of sublethally or supralethally irradiated NOD/SCID mice was 2.3 (1.4 to 2.8) and 2.5 (1.6 to 2.7), respectively. Because we did not observe any significant differences in the seeding efficiencies of the various stem cell subsets, it may be assumed that the SRC seeding efficiency in NOD/SCID mice is similarly low. Our data indicate that the seeding efficiency of a graft can be of great influence when assessing stem cell frequencies in in vivo repopulation assays.

Entities:  

Mesh:

Year:  1999        PMID: 10556189

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.

Authors:  H Glimm; W Eisterer; K Lee; J Cashman; T L Holyoake; F Nicolini; L D Shultz; C von Kalle; C J Eaves
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Ex vivo expansion of human umbilical cord blood CD34+ cells in a collagen bead-containing 3-dimensional culture system.

Authors:  Han-Soo Kim; Jong Baeck Lim; Yoo Hong Min; Seung Tae Lee; Chuhl Joo Lyu; Eun Seok Kim; Hyun Ok Kim
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

3.  Mesenchymal stem cell therapy: Two steps forward, one step back.

Authors:  James Ankrum; Jeffrey M Karp
Journal:  Trends Mol Med       Date:  2010-03-23       Impact factor: 11.951

4.  Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC.

Authors:  Halvard Bonig; Gregory V Priestley; Vivian Oehler; Thalia Papayannopoulou
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

5.  Intrabone transplantation of CD34+ cells with optimized delivery does not enhance engraftment in a rhesus macaque model.

Authors:  Kate Stringaris; Robert F Hoyt; Jan K Davidson-Moncada; Jeremy M Pantin; John F Tisdale; Naoya Uchida; Lydia N Raines; Robert Reger; Noriko Sato; Cynthia E Dunbar; Timothy J Hunt; Randall R Clevenger; Allen Krouse; Mark E Metzger; Aylin C Bonifacino; William Telford; Peter L Choyke; Theresa Engels; Robert E Donahue; Richard W Childs
Journal:  Blood Adv       Date:  2020-12-22

6.  A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.

Authors:  N Kurita; M Gosho; Y Yokoyama; T Kato; N Obara; M Sakata-Yanagimoto; Y Hasegawa; N Uchida; S Takahashi; Y Kouzai; Y Atsuta; M Kurata; T Ichinohe; S Chiba
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

7.  Effects of spleen status on early outcomes after hematopoietic cell transplantation.

Authors:  G Akpek; M C Pasquini; B Logan; M-A Agovi; H M Lazarus; D I Marks; M Bornhaeüser; O Ringdén; R T Maziarz; V Gupta; U Popat; D Maharaj; B J Bolwell; J D Rizzo; K K Ballen; K R Cooke; P L McCarthy; V T Ho
Journal:  Bone Marrow Transplant       Date:  2012-12-10       Impact factor: 5.483

8.  Maitake beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse.

Authors:  Hong Lin; Elisa De Stanchina; Xi Kathy Zhou; Yuhong She; Danthanh Hoang; Sandy Wy Cheung; Barrie Cassileth; Susanna Cunningham-Rundles
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-14

9.  P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells.

Authors:  Byeong-Chel Lee; Tao Cheng; Gregor B Adams; Eyal C Attar; Nobuyuki Miura; Sean Bong Lee; Yoriko Saito; Ivona Olszak; David Dombkowski; Douglas P Olson; Julie Hancock; Peter S Choi; Daniel A Haber; Andrew D Luster; David T Scadden
Journal:  Genes Dev       Date:  2003-07-01       Impact factor: 11.361

Review 10.  Biology of normal and acute myeloid leukemia stem cells.

Authors:  John E Dick; Tsvee Lapidot
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.